title: CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
source: Yahoo
date: 2025-10-14
url: https://finnhub.io/api/news?id=cb3c304c46efc1a19f8e073272102dc2f8b93e689abfb08a555f2caff8461a2e
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
